JY
STLN

Jeff Yass’s Starling Oncology STLN Stock Holding History

Jeff Yass’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$484K Sell
89,200
-25,700
-22% -$108K ﹤0.01% 9995
2026
Q1 		$353K Buy
114,900
+89,600
+354% +$275K ﹤0.01% 10510
2025
Q4 		$90.1K Buy
25,300
+10,100
+66% +$37.5K ﹤0.01% 11510
2025
Q3 		$53K Buy
+15,200
New +$52.1K ﹤0.01% 11842

Other funds holding STLN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Jeff Yass's STLN Position: Q2 2026 in Review

Jeff Yass sold out of Starling Oncology (STLN) in Q2 2026, closing a stake of 92,869 shares — an estimated $390K sold.

Jeff Yass first reported a position in STLN in Q3 2022 and held it in 8 quarters. The position peaked at $1.05M in Q4 2025. 119 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

  • Jeff Yass reported no remaining Starling Oncology position as of Q2 2026 after selling out during the quarter.
  • Jeff Yass sold 92,869 Starling Oncology shares in Q2 2026, an estimated $390K.
  • Jeff Yass first reported a position in Starling Oncology in Q3 2022 and held it in 8 quarters.
  • Jeff Yass's Starling Oncology position peaked at $1.05M in Q4 2025.
  • 119 funds tracked by Wall St. Rank held Starling Oncology as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.